This month we’re talking about advances in prostate cancer immunotherapy. The interviews are informative and lucid— quite an achievement as cancer immunotherapy is quite complex. One important takeaway is that Provenge (sipuleucel-T) is much more effective when the tumor burden is low. In my experience, this treatment is often offered when metastatic spread is too extensive for optimal effectiveness. Perhaps cost is one reason. Provenge (sipuleucel-T) is about $90,000. Many patients face 20% copays, which mean outof- pocket fees of $18,000. Charles Myers, MD.